However, despite a higher incidence of HER-2 mutations in cholangiocarcinoma compared with gallbladder cancers, five patients with HER-2 mutated cholangiocarcinoma showed no response to HER-2-directed therapy in the same study [36]. Here, ERBB2 is linked to cholangiocarcinoma.